Lipozem reviews on Reddit present a mixed yet informative perspective on this natural weight loss supplement. Users ...

PrimeBiome is a gut-focused supplement formulated to help improve skin clarity, support healthier digestion, and foster an ...

Pursuant to the New OTBC Service Agreement, OTBC will be paid $100,000 in cash, which shall be payable in quarterly installments over 12 months, and receive an option pursuant to the Company’s stock ...

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that, pursuant to a securities purchase agreement (the “Purchase Agreement”) with Blue Harbour Asset Management L.

DBV Technologies publie son « Form 10-K » américain et son Document d’Enregistrement Universel 2024 DBV Technologies (Euronext : DBV – ISIN : FR0010417345 - Nasdaq : DBVT), une société ...

The filing, for the year ended December 31, 2024, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“URD”) with the ...

This release has been authorised by the directors of Immuron Limited. Steven Lydeamore Chief Executive Officer ...

Fulcrum granted the new employees an aggregate of 96,800 options to purchase shares of the company’s common stock at an exercise price of $2.72 per share, the closing price per share of Fulcrum’s ...

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on April 9, 2025, the compensation ...

Dr. Aljurf is the first recipient from outside the United States, underscoring his global impact on hematopoietic stem cell ...

The inducement equity awards were granted effective as of April 7, 2025 and consist of (i) for Mr. Cella, a non-statutory stock option to purchase up to 26,000 shares of Ocular’s common stock and a ...

WOBURN, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...